Beyond the Device: Dr. Martha Boeckenfeld on Scaling Tremor Solutions

In a recent LinkedIn post, Dr. Martha Boeckenfeld discusses the profound gap between innovative assistive technologies and their widespread, equitable accessibility. While devices like Liftware offer life-changing restoration of dignity for individuals with tremors, Dr. Boeckenfeld highlights that the true challenge lies not in the invention itself, but in the systems required to deliver it effectively to the millions who need it.

The post opens with a poignant narrative of Stefanie Putnam, a C4–5 quadriplegic who found a renewed sense of normalcy through Liftware, an electronically stabilized utensil designed to reduce hand tremors. Dr. Boeckenfeld uses Stefanie’s experience to illustrate the immediate, personal impact of such technology.

“Stefanie got her soup back. And with it, the nerve to go out again—meet friends, eat in public, feel normal.”

However, Dr. Boeckenfeld quickly pivots from this individual success story to a broader, systemic analysis. She points out that while Liftware has reached hundreds of thousands of users, it represents a fraction of the tens of millions worldwide living with conditions like essential tremor and Parkinson’s disease. This disparity, she argues, reveals critical failures in the ecosystem surrounding the technology.

The High Cost of Dignity

A primary barrier identified by Dr. Boeckenfeld is the prohibitive cost of many assistive devices. Liftware, for instance, comes with a $295 starter kit price tag, which is typically borne out of pocket as insurance and public payers rarely offer coverage. This financial hurdle disproportionately affects those who could benefit most, making reliance on donations and charity partners a necessity for broader reach.

As Dr. Boeckenfeld notes:

“Cost: $295 for a starter kit, usually out of pocket. Insurance and public payers rarely cover it. Reaching people who can’t pay depends partly on donations and charity partners.”

Geographical and Clinical Access Gaps

Beyond cost, Dr. Boeckenfeld emphasizes the limitations in geographical and clinical adoption. Liftware, she observes, is currently only sold in the United States, leaving individuals in other countries without an official avenue to acquire the device. Furthermore, the technology has not been widely integrated into standard clinical practice.

According to Dr. Boeckenfeld, the lack of clinical adoption means that:

“it’s not part of standard tremor guidelines. Many neurologists don’t prescribe it—or even mention it. Patients and clinicians aren’t sure what it’s worth over the long run.”

This absence from clinical guidelines and a general uncertainty about long-term value hinder its widespread recommendation and use by healthcare professionals.

Limitations and Stigma

Dr. Boeckenfeld also touches upon the inherent use limitations of such devices and the persistent issue of stigma. While effective for mild to moderate tremors during eating, devices like Liftware are not designed for tasks like writing or drinking. Moreover, the public nature of using an assistive device can itself be a deterrent.

In Dr. Boeckenfeld’s view, the device, while freeing at home, can feel like a public announcement of a disability:

“Stigma: at home, it’s freeing. In a restaurant, it can feel like a signal flare. Some people buy it, then leave it in a drawer to avoid the looks.”

This highlights a crucial social barrier that technology alone cannot overcome. The desire to avoid unwanted attention can lead to devices being abandoned, negating their potential benefits.

Scaling Impact: From One to Millions

The core of Dr. Boeckenfeld’s analysis centers on the concept of scale. She contrasts the success of a single user, like Stefanie, with the systemic changes needed to impact millions. True scale, as she outlines, involves:

• Ten clinics treating the condition as routine care to create local access.
• A hundred countries with payer coverage to establish tremor management as a standard care pathway, rather than a cause of isolation.

Ultimately, Dr. Boeckenfeld concludes that while the ingenuity to restore dignity through technology is present, the crucial challenge lies in developing the robust systems necessary for widespread, equitable delivery and adoption. The success of a single product is only the first step; the true measure of progress is in building the infrastructure that ensures such innovations reach everyone who needs them.